Q-omics provides the consensus-scored B3GNT9 profile across patient tissues and cancer cell-line models. B3GNT9 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, B3GNT9 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, B3GNT9 RNA expression shows 19,581 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LGG, HNSC, and TGCT as cancer lineages where B3GNT9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for B3GNT9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes B3GNT9 survival associations across molecular data types. B3GNT9 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible B3GNT9 RNA expression–survival associations across cancer types. High B3GNT9 expression shows unfavorable associations in LGG, BLCA, LIHC, STAD and ACC, but favorable associations in KIRC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for B3GNT9 RNA expression.
This table summarizes B3GNT9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for B3GNT9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. B3GNT9 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, COAD, KIRC and BRCA. The HNSC box plot shows higher B3GNT9 RNA expression in tumor versus normal tissue (log2 FC = +1.615, t-test p < 0.001).
This table shows molecular features associated with B3GNT9 in patient tissues and cancer cell lines. In patient samples, B3GNT9 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, B3GNT9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
